Published in Gene Therapy Weekly, May 1st, 2008
"The mechanistic basis of this distinction remains unclear and the BCL6 targets have been only partially explored. Here we describe how NFKB activity is increased after BCL6 silencing by shRNA in DLBCL cells, leading us to propose that BCL6 represses NFKB activity. We also demonstrate that this repression is brought about by a mechanism involving...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.